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Background: Little information is available on the use of chest computed tomography (CT) to predict breast tumor
size in breast cancer, despite the fact that chest CT examinations are being increasingly used. The purpose of this
study was to evaluate the value of chest CT for predicting breast tumor size using pathology measurements as
reference standards.
Methods: Tumor sizes (defined as greatest diameter) were retrospectively measured on the preoperative chest CT
images of 285 patients with surgically proven unifocal, invasive breast carcinoma. Greatest tumor diameters as
determined by chest CT and pathologic examinations were compared by linear regression and Spearman’s rho
correlation analysis. Concordance between CT and pathology results was defined as a diameter difference of
<5 mm. Subgroup analyses were also performed with respect to tumor size (<20 mm or ≥20 mm) and histological
subtype (invasive ductal carcinoma(IDC) or non-IDC).
Results: CT and pathology measured diameters were found to be linearly related (size at pathology = 1.086 × CT
determined tumor size - 1.141; Spearman’s rho correlation coefficient = 0.84, P<0.001). Most tumors (n = 228, 80.0%)
were concordant by chest CT and pathology, but 36 tumors (12.7%) were underestimated by CT (average
underestimation, 11 mm; range, 6–36 mm) and 21 tumors (7.4%) were overestimated (average overestimation by
CT, 10 mm; range, 6–19 mm). The concordance rate between the two sets of measurements was greater for tumor
of <20 mm and for IDC (P<0.001 and P = 0.011, respectively).
Conclusions: Tumor size by chest CT is well correlated with pathology determined tumor size in breast cancer
patients, and the diameters of the majority of tumors by chest CT and pathology differed by <5 mm. In addition,
the concordance rate was higher for breast tumors of <20 mm and for tumors of the IDC histologic subtype.
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Breast cancer is the most common malignancy in
women, and accounts for 15% of all cancers [1]. The ac-
curate estimation of tumor size and extent in breast can-
cer is essential for surgical planning and minimizing
local recurrence after surgery [2,3], and recently, chest
computed tomography (CT) has been used to detect* Correspondence: oneshot0229@gmail.com
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reproduction in any medium, provided the orpulmonary and hepatic metastasis in patients with breast
cancer before surgery. However, chest CT screening is
not currently recommended in operable and asymptom-
atic patients with breast cancer [4,5], although the use of
chest CT examinations in breast cancer patients is un-
doubtedly increasing. Furthermore, a review of the lit-
erature revealed that no study has yet addressed the use
of chest CT for determining breast tumor size. Accord-
ingly, the purpose of this study was to assess the value
of chest CT for determining breast tumor size using
pathology measurements as reference standards.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Clinicopathologic characteristics of the study
subjects
Characteristics Tumors <20 mm
on CT (n= 139)
Tumors ≥20 mm
on CT (n= 146 )
P values




















Positive 95 81 0.164c
Negative 44 65
PR status

















Grade 1 26 8 0.091c
Grade 2 82 73
Grade 3 31 65
Unknown
Table 1 Clinicopathologic characteristics of the study
subjects (Continued)
Operation type




a Mean values with standard deviations (numbers in parentheses are ranges).
b Two-sample t- test.
c Chi-squared test.
d Others including invasive papillary carcinoma (n= 6), invasive micropapillary
carcinoma (n= 5), mucinous carcinoma (n=4), metaplastic carcinoma (n=4),
invasive tubular carcinoma (n= 3), invasive apocrine carcinoma (n= 3),
neuroendocrine carcinoma (n=1), invasive carcinoma with squamous
differentiation (n=1).
e Scarff-Bloom-Richardson grade system.
ER, estrogen receptor; PR, progesterone receptor.
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Patients
We retrospectively searched archived records in a prac-
tice specializing in breast surgery from April 2010 to
January 2012 for breast cancer patients that underwent
chest CT before surgical treatment. The inclusion cri-
teria adopted were newly diagnosed, biopsy-proven,
unifocal breast cancer with a positive chest CT scan. Fi-
nally, 285 patients (mean age, 48.79 years; range, 20–79
years) were included. Baseline characteristics of the
study cohort are provided in Table 1.
Gross and histopathologic examinations of surgical
specimens were performed by staff pathologists. Cross-
sections of formalin-fixed paraffin-embedded specimens
were obtained at 5-mm intervals perpendicular to the
line connecting the nipple and the tumor center. Speci-
mens were examined microscopically using hematoxylin
and eosin staining. Lesion sizes were measured and lar-
gest tumor diameter was defined as tumor size.
Histopathologic diagnosis revealed invasive ductal
carcinoma (IDC) in 86%, invasive lobular carcinoma
(ILC) in 4.5%, invasive papillary carcinoma in 2.1%, and
othersin 7.4%. The parameters used for multidetector
computed tomography (MDCT) (Somatom Sensation 16
or 64 scanners, Siemens Medical Solutions, Forchheim,
Germany) examinations were as follows: 100–120 kVp,
170 mAs, 5-mm collimation, a 10 mm/s table feed with
a 1-s rotation time, 5.0-mm slice thickness, and 2.5–5.0
mm intervals. Synthetic sagittal and coronal images were
reformatted at intervals of 3 mm and fully covered the
region from anterior skin to the back of the chest. The
effective dose for chest CT was 4.0 mSv, based on a
standard patient model using an anthropomorphic phan-
tom, and a conversion factor of 0.017 mSv/(mGy.cm)
was used to convert dose-length product to effective
dose [6]. Prior to chest CT, all patients fasted for >6 h.
Iopromide (120 mL; Ultravist; Bayer Schering Pharma,
Berlin) was injected intravenously at a rate of 4 mL/s,
and CT images were obtained 30–40 s later. Our
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study, and the requirement for informed patient consent
was waived.
Image analysis
A subspecialty-trained chest radiologist and a third-year
radiology resident retrospectively measured maximum
diameters of breast tumors on CT images by consensus
and compared these with pathologic results. CT deter-
mined tumor sizes were also analyzed for concordance
with pathologic tumor sizes.
Concordance between CT and pathologic diameters
was defined as a tumor size difference of <5 mm.
When a CT measured size was >5 mm smaller than
pathologic tumor size, CT determined tumor size was
considered an underestimation, and conversely, when
CT size was >5 mm larger than pathologic tumor size,
it was considered an overestimation. In addition,
concordance rates between IDC and non-IDC patients
and between patients with a CT determined tumor
diameter of <20 mm (Group 1) and ≥20 mm (Group 2)
were compared.
Statistical analysis
Maximum chest CT and pathology determined tumor
sizes were compared by linear regression and Spearman’s
rho correlation analysis. The chi-squared test was used
to analyze concordances rates between chest CT and
pathology with respect to tumor size and histologic type.
Statistical significance was accepted at the 95% confi-
dence level (P<0.05). A commercially available software
program was used for data processing and analysis
(PASW, version 17.0; SPSS, Chicago, IL, USA).
Results
Overall, longest tumor diameters as determined by chest
CT (average, 21 mm, range, 2–74 mm) and pathology
(average, 22 mm; range, 3–90 mm) were not significantly
different (P = 0.059), and a linear relation was found
between the two (pathology determined tumor size =Table 2 Comparison of CT and pathologically determined tum
Size (median ± SD) Concord
n (%) CT Pathology
Overall 285 (100) 19±10 20±13 228 (80)
CT groupa
Group 1 (<20 mm) 139 (49) 15±5 13±4 123 (88)
Group 2 (≥20 mm) 146 (51) 27±10 30±13 105 (72)
Tumor typeb
IDC 245 (86) 20±10 20±12 202 (83)
Non-IDC 40 (14) 18±11 19±14 26 (65)
a Comparison of group 1 to group 2, P<0.001.
b Comparison across tumor types, P = 0.011.1.086 × CT determined tumor size - 1.141; Spearman’s
rho correlation coefficient, 0.84; P<0.001).
Tumor sizes were concordant in 228 of the 285
patients (80%). However, 36 tumors (12.7%) were
underestimated by CT by an average of 12 mm (range,
6–36 mm) and 21 tumors (7.4%) were overestimated by
an average of 10 mm (range, 6–19 mm). The concord-
ance rate was higher for tumors of <20 mm (88.5% vs.
71.9% for tumor size <20 mm vs. tumor size ≥20 mm,
P<0.001) and for IDC (82.4% vs. 65.0% for IDC vs. non-
IDC, P = 0.011) (Table 2).
Discussion
A number of imaging modalities are used to assess
tumor size and extent in breast cancer to determine
optimal treatment. Mammography and ultrasonography
are the first choices for the screening and diagnosis of
breast cancer, but mammography is limited in pre-
menopausal women with dense breasts and ultrasonog-
raphy is not reliable enough to visualize tumor extensions
when tumors exhibit extensive intraductal spread [7].
Breast magnetic resonance imaging (MRI) has attracted
much attention recently because its ability to detect breast
lesions sufficient to allow the accurate visualization of
intraductal lesions around main tumors [7,8]. However, al-
though MRI offers the advantage of sensitivity, it tends to
overestimate tumor size and is limited by a relatively high
false-positive rate, and thus, requires additional biopsies
and increases patient anxiety, time, and costs [9-11]. In
addition, MRI cannot be performed in patients with claus-
trophobia and is usually performed in the prone position,
whereas surgery is performed with the patient supine.
ChestCT examinations, on the other hand, are performed
in the supine position, and thus, the positions of breasts
in chest CT images better matches the surgical approach.
Furthermore, due to the technological improvements of-
fered by MDCT, several authors have concluded that CT
of the breast provides an accurate preoperative means of
assessing tumor extent and size [8,12-14]. However, breast
CT in these reports had different acquisition techniqueor sizes
ance with CT (%) Discordance with CT (%)
Overestimated by CT Underestimated by CT
21 (7) 36 (13)
15 (11) 1 (1)
6 (4) 35 (24)
18 (7) 25 (10)
3 (8) 11 (28)
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tice, because the field of view is limited to the breast
region and examinations require multiple scans, includ-
ing precontrast CT scan and postcontrast CT scan at 70
to 100 s after contrast administration [13,15,16], or a
dynamic acquisition technique (1, 3, and 8 min after
contrast administration), which inevitably increases ra-
diation dose [17]. In previous studies [17-19], the radi-
ation dose required for breast CT was reported to be 28
mSv, which is approximately 10 times greater than that
used for standard mammographic examinations (2.8
mSv), and seven times higher than that required for a
chest CT examination.
For the assessment of tumor size in breast cancer, sev-
eral authors have addressed the accuracies of mammog-
raphy, ultrasonography (US), and magnetic resonance
imaging (MRI) [20-24]; Ramirez et al. [22] concluded
that generally, breast mammography determined tumor
size correlated better with histopathologic size than
MRI or US determined tumor sizes. However, MRI is
regarded to be more accurate than mammography or
ultrasonography in the ILC subtype, which tends to
underestimate the sizes of ILC in up to 70%, and 80% of
cases, respectively [23,24]. However, to the best of our
knowledge, no previous study has addressed tumor size
estimation by chest CT in breast cancer patients.
Because the incidence of metastasis is low and false-
positive findings are more common than true-positive
findings [4,5], the current National Comprehensive
Cancer Network (NCCN) guidelines do not recommend
the routine use of chest CT in operable breast cancer.
Nevertheless, chest CT exanimations are being increas-
ingly used in breast cancer to evaluate pulmonary and
hepatic metastases [5,23,24]. Somewhat surprisingly, no
report has been issued regarding the predictive value of
chest CT for the evaluation of tumor size in breast can-
cer. In the present study, we found a positive correlation
between chest CT and pathologically determined tumor
sizes and that tumors sizes differed by <5 mm in 80% of
our cohort. Furthermore, the concordance rate between
CT and pathologic findings was higher for breast tumors
of <20 mm and for those of the IDC histologic subtype.
Although current guidelines and available evidence do
not support the routine preoperative chest CT evalu-
ation of operable breast cancer, in some patients with a
respiratory or abdominal symptom or who deny other
imaging modalities, chest CT could provide an alterna-
tive means of evaluating tumor size, especially when the
tumor is <20 mm of the IDC subtype.
This study had several limitations that warrant consid-
eration. First, it is inherently limited by its retrospective
design. In particular, the study is subject to selection
bias, because women were selected for chest CT at the
discretion of a breast surgeon, and breast cancers notvisualized by chest CT were not included in the study.
Second, we did not compare CT determined tumor sizes
with ultrasonography, mammography, or breast MRI
determined sizes, because not all patients underwent
ultrasonography, mammography, or MRI, and because
imagings were performed at different times. A prospect-
ive study is required to compare the abilities of chest
CT, ultrasonography, mammography, and breast MRI to
determine breast cancer size. Third, formalin fixation
affects solid tissue measurements. Pritt and colleagues
[25] observed 4% of breast cancer specimens decreased
in size after overnight formalin fixation and that 40%
shrank after processing and mounting.
Conclusions
The present study shows that chest CT can be used to
predict breast tumor size reliably in patients with breast
cancer. In fact, chest CT determined breast tumor sizes
were found to be well correlated with pathology-
determined sizes, and for most, the size difference was <5
mm. In addition, the concordance rate between chest CT
and pathology was found to be greater for breast tumors
of <20 mm and for the IDC subtype.
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